Acute kidney injury in patients on SGLT2 inhibitors: A propensity-matched analysis

Diabetes Care

Volumn 40, Issue 11, 2017, Pages 1479-1485

  Nadkarni, Girish N ^a   Ferrandino, Rocco ^a   Chang, Alexander ^b   Surapaneni, Aditya ^c   Chauhan, Kinsuk ^a   Poojary, Priti ^a   Saha, Aparna ^a   Ferket, Bart ^a   Grams, Morgan E ^c   Coca, Steven G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CHOLESTEROL; GLUCOSIDE; HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROPENSITY SCORE; REGISTER; RISK ASSESSMENT; SENSITIVITY ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; BODY MASS; CHEMICALLY INDUCED; DRUG EFFECTS; INCIDENCE; KIDNEY; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ACUTE KIDNEY INJURY; AGED; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; BODY MASS INDEX; CANAGLIFLOZIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85033219798     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1011     Document Type: Article

References (15)

1. Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA 2014;312:1218-1226
2. Fox CS, Golden SH, Anderson C, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015;38:1777-1803
3. Triggle CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis 2014;5:245-268
4. Zinman B, Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
5. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS ProgramCollaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl JMed. 12 June 2017 [Epub ahead of print]. DOI:10. 1056/NEJMoa1611925
6. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin andprogression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334
7. U. S. Food and Drug Administration. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) [article online], 2016. Available from https://www. fda. gov/Drugs/DrugSafety/ucm505860. htm. Accessed 21 April 2017
8. Girman CJ, Kou TD, Brodovicz K, et al. Risk of acute renal failure in patients with type 2 diabetes mellitus. Diabet Med 2012;29:614-621
9. NadkarniGN, GottesmanO, Linneman JG, et al. Development and validation of an electronic phenotyping algorithmfor chronic kidney disease. AMIA Annu Symp Proc. 2014;2014:907-916
10. Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit Care 2013;17:204
11. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther 2014;5: 355-366
12. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury fromSGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 2016;12:711-712
13. HeymanSN, KhamaisiM, RosenS, RosenbergerC, Abassi Z. Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care 2017; 40:e40-e41
14. Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type2diabetes: A pooled analysis. Curr Med Res Opin 2017;33:553-562
15. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371:58-66